Blood Industry Reps Will Be Tapped Under “Realist” HHS Panel Approach
This article was originally published in The Gray Sheet
Executive Summary
HHS will restructure its Blood Safety & Availability Advisory Committee to openly acknowledge industry reps as panel members, rather than retain company employees with the use of regulatory waivers